Phase II/III SUNFISH part 2: 24-month efficacy and safety of risdiplam in patients with Type 2 or non-ambulant Type 3 spinal muscular atrophy

Roche Neuroscience and Rare Disease franchise update

Q&A

Paulo Fontoura, M.D. Ph.D., Global Head Neuroscience and Rare Diseases Clinical Development

Simona Skerjanec, Therapeutic Area Head Neuroscience and Rare Diseases, Global Product Strategy

Karl Mahler, Head of Investor Relations and Roche Group Planning